| |
Mean ± SD or median (min,max) or number (%)
|
p value
|
|---|
|
Group 1 (n = 11)
|
Group 2 (n = 9)
|
Group 3 (n = 8)
|
Group 4 (n = 8)
|
|---|
|
Age, year
|
47.94 ± 7.73
|
45.33 ± 8.66
|
41.12 ± 7.72
|
43.00 ± 7.41
|
0.23b
|
|
BMI, kg/m2
|
22.48 ± 2.40
|
22.68 ± 3.64
|
23.63 ± 3.07
|
21.61 ± 2.45
|
0.59b
|
|
Male, no.
|
8 (72.7)
|
7 (77.8)
|
4 (50)
|
4 (50)
|
0.48c
|
|
Diabetes, no.
|
0
|
1 (11.1)
|
0
|
0
|
0.41c
|
|
Hypertension, no
|
1 (9.1)
|
1 (11.1)
|
0
|
0
|
0.48c
|
|
PIs, no.
|
2 (18.2)
|
1 (11.1)
|
0
|
1 (12.5)
|
0.50c
|
|
NNRTI, no.
|
9 (81.8)
|
8 (88.9)
|
8 (100)
|
7 (87.5)
|
|
Suppressed HIV viral load, nod
|
9 (81.8)
|
8 (88.9)
|
8 (100)
|
8 (100)
|
0.27c
|
|
HIV duration, years
|
5.61 ± 5.21
|
11.11 ± 3.79
|
6.61 ± 4.51
|
8.78 ± 7.11
|
0.13b
|
|
CD4, cell/cmm
|
514.27 ± 331.71
|
678.22 ± 438.85
|
612.62 ± 270.87
|
443.88 ± 152.96
|
0.45b
|
|
Creatinine, mg/dL
|
0.90 ± 0.19
|
0.95 ± 0.28
|
0.94 ± 0.35
|
0.73 ± 0.13
|
0.29b
|
|
SGPT, mg/dL
|
35.81 ± 24.46
|
35.66 ± 15.02
|
30.13 ± 12.77
|
27.50 ± 8.18
|
0.67b
|
|
HDL-c, mg/dL
|
52.07 ± 13.23
|
53.04 ± 12.08
|
57.73 ± 20.93
|
58.13 ± 23.15
|
0.83b
|
|
LDL-c, mg/dL
|
175.75 ± 36.90
|
186.99 ± 24.60
|
163.01 ± 9.65
|
173.04 ± 35.24
|
0.43b
|
|
TC, mg/dL
|
222.0 (197,301)
|
245.0 (227,353)
|
242.5 (191,285)
|
242.0 (202,297)
|
0.48a
|
|
TG, mg/dL
|
134.0 (64,390)
|
176.00 (53,620)
|
106.50 (58,499)
|
109.0 (52,367)
|
0.54a
|
|
CPK, mg/dL
|
131.0 (46,876)
|
150.0 (87,234)
|
133.5 (60,289)
|
123.0 (79,532)
|
0.96a
|
- Group 1, pravastatin then combination; Group 2, combination then pravastatin; Group 3, phytosterols then combination; Group 4, combination then phytosterols.
-
aKruskal–Wallis Test.
-
bOne-way ANOVA.
-
cLikelihood Ratio test.
-
dSuppressed HIV viral load defined by HIV viral load <50 copies/ml.
